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Increased airway glucose  
increases airway bacterial  
load in hyperglycaemia
Simren K. Gill1,2, Kailyn Hui2, Hugo Farne3, James P. Garnett4,†, Deborah L. Baines4, 
Luke S.P. Moore5, Alison H. Holmes5, Alain Filloux2 & John S. Tregoning1
Diabetes is associated with increased frequency of hospitalization due to bacterial lung infection. We 
hypothesize that increased airway glucose caused by hyperglycaemia leads to increased bacterial 
loads. In critical care patients, we observed that respiratory tract bacterial colonisation is significantly 
more likely when blood glucose is high. We engineered mutants in genes affecting glucose uptake 
and metabolism (oprB, gltK, gtrS and glk) in Pseudomonas aeruginosa, strain PAO1. These mutants 
displayed attenuated growth in minimal medium supplemented with glucose as the sole carbon 
source. The effect of glucose on growth in vivo was tested using streptozocin-induced, hyperglycaemic 
mice, which have significantly greater airway glucose. Bacterial burden in hyperglycaemic animals 
was greater than control animals when infected with wild type but not mutant PAO1. Metformin pre-
treatment of hyperglycaemic animals reduced both airway glucose and bacterial load. These data 
support airway glucose as a critical determinant of increased bacterial load during diabetes.
Diabetes is associated with an increased risk of bacterial lung infection, especially when there are underlying 
chronic lung conditions1,2. It has recently been proposed that uncontrolled hyperglycaemia in diabetics increases 
lung glucose, providing a richer growth medium that facilitates bacterial infection3. Of note, diabetes where gly-
caemia is controlled is not associated with increased risk of bacterial infection4. Levels of glucose in the lungs are 
tightly regulated and are up to 12 times lower in the airway surface liquid lining the lungs than circulating levels5. 
Glucose concentration in the airway is kept low by the action of facilitative glucose transporters GLUT -1, 2 & 
GLUT-106,7, highlighting the importance of limiting glucose availability in the lungs.
In differentiated airway cell culture models, it has been observed that increasing the basolateral glucose concen-
tration increases the growth of the respiratory pathogens Staphylococcus aureus8 and Pseudomonas aeruginosa6,8,9. 
The aim of the current study was to determine the effect of glucose on bacterial growth in vivo and therefore 
directly link bacterial glucose metabolism with increased respiratory tract bacterial load in hyperglycaemia. To 
investigate this we used P. aeruginosa, a Gram-negative opportunistic bacterial pathogen, which is a major cause 
of respiratory infections. Chronic P. aeruginosa infections are most commonly associated with patients with cystic 
fibrosis (CF) and chronic obstructive pulmonary diseases (COPD)10, but importantly P. aeruginosa is increas-
ingly diagnosed in diabetic patients with pneumonia/lung infection1. It is of note that diabetes is diagnosed in 
40–50% of CF patients11. Members of the Pseudomonas genus are able to adapt to a wide range of environments 
with over 9% of their large genome encoding regulatory elements, which enables Pseudomonas to respond to 
changes in environmental conditions including nutrient availability12–14. Pseudomonas has a complex carbohy-
drate utilisation pathway, with succinate as the preferred carbon source but growth is nicely supported by the 
availability of glucose. The genes that control the uptake and metabolism of glucose in P. aeruginosa are found 
mostly in an operon which encodes the genes oprB, gltK, gtrS and glk, and 3 additional genes encoding a putative 
ABC transporter15. OprB and GltK are involved in glucose transport across the outer and inner membranes, 
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respectively, Glk is the glucokinase that catalyses the reaction of glucose to glucose-6-phosphate for entry into the 
Entner-Doudoroff pathway and GtrS, together with GltR, forms a two-component regulatory system.
Here we designed an elegant strategy to evaluate the effect of glucose on bacterial lung infection. We inves-
tigated the clinical association between hyperglycaemia and airway bacterial colonisation, particularly with 
P. aeruginosa, in the context of critical care. We then generated P. aeruginosa mutants in the oprB, gltK, gtrS 
and glk genes and used these mutant strains in in vitro and in vivo models. The mutants had drastically reduced 
growth in minimal medium containing glucose as the sole carbon source, whereas they were unaltered when 
grown in rich medium. In order to explore the effect of elevated glucose with minimal effects on the immune 
response, we used streptozocin induced diabetes16, instead of genetically obese mice (with mutations in leptin 
signalling), which have a complex phenotype and impaired immune responses17. Remarkably, we observed that 
streptozocin induced hyperglycaemia led to increased bacterial load in the airways when mice were infected 
with wild type PAO1 but not with the glucose uptake and metabolism mutants. We thus clearly established that 
increased glucose is a major factor in the increased bacterial infection in diabetes and therefore informed and 
preventive measures should be taken with these patients.
Results
Colonisation of the respiratory tract with organisms among critical care patients is associated 
with high blood glucose. 1,148 admissions to two central London teaching hospital critical care units were 
identified during the study period (2013–2014); of these 664 had a random blood glucose electronically recorded 
on admission and were able to be evaluated. Among these 664 patients 241 had a random blood sugar above 
11.1 mmol/l and were categorised as high risk for diabetes according to the WHO definitions18. After de-dupli-
cation 174 patients had samples which grew an organism, 4 of these were yeasts and were discounted leaving 
170 patients with bacteria isolated from their sputum in the 7 days succeeding admission. Chi squared analysis 
demonstrated a statistically significant (p = 0.0002) difference in the likelihood of an organism being isolated 
between those who had a high blood sugar (of whom 39% had a positive sputum culture) and those who had a 
low blood sugar (of whom 18% had a positive sputum culture) (Table 1). P. aeruginosa was the most frequently 
isolated organism among critical care patients.
Deletion of P. aeruginosa genes involved in glucose uptake and utilisation attenuates growth 
when glucose is the sole carbon source. Having observed a greater level of bacterial colonisation in 
patients with high glucose, and a high prevalence of P. aeruginosa in these patients, we wished to determine the 
effect of bacterial glucose uptake and metabolism on colonisation. To test the effect of airway glucose on bacterial 
growth, we generated P. aeruginosa mutants defective in glucose uptake and utilisation (Fig. 1A,B). We engi-
neered clean deletions in either the oprB, gltK, gtrS or glk genes using a mutator plasmid based on the pKNG101 
suicide vector as described before19. The deletion was confirmed using primers designed in the upstream and 
downstream regions of the targeted gene. We observed no difference in growth between the mutants and paren-
tal strain PAO1 in rich medium (LB) (Fig. 1C), indicating that the mutations did not cause any global growth 
Highest glucose on day 
of ICU admission ≥ 11.1 
mmol/l
Highest glucose on 
day of ICU admission 
<11.1 mmol/l
Number 241 423
Mean Age 62.6 years 69.6 years
Proportion female 41% 47%
Admission category
 Medicine 62% 57%
 Surgery 38% 43%
Culture positive sputum sample in the first 7 
days of critical care admission 94 (39%) p = 0.0002 76 (18%)
Organism isolated
 Pseudomonas spp. 30 (32%) 20 (26%)
 Staphylococcus aureus 13 12
 Klebsiella spp. 12 11
 Escherichia coli 12 9
 Enterobacter spp. 11 6
 Stenotrophomonas maltophilia 7 3
 Serratia marcescens 3 6
 Streptococci 0 6
 Citrobacter spp. 3 1
 Proteus spp. 2 1
 Acinetobacter spp. 1 0
 Morganella morganii 0 1
Table 1.  Association between blood glucose at admission to critical care and bacterial colonisation of the 
lung in the first 7 days of admission.
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defects. All strains tested entered log phase after 2 hours and growth began to slow by 24 hours after inoculation. 
Bacteria were unable to grow in minimal medium in the absence of a carbon source (data not depicted). When 
the different strains were compared using minimal medium supplemented with glucose, there was a significant 
decrease in growth for the mutants as compared to PAO1 (P < 0.001, Fig. 1D). When minimal media was sup-
plemented with fructose, another monosaccharide, which enters the cell by different proteins bacterial growth 
was similar between all strains (Fig. 1E). When growth was supplemented with succinate (Fig. 1F), the preferred 
carbon source for P. aeruginosa, the glk and gltK mutants grew with a similar kinetic to the wild type, but the 
gtrS mutant was significantly attenuated (p < 0.05 at 24 hrs) and interestingly the oprB mutant had significantly 
greater growth. A similar pattern was observed in the glucose supplemented media, with the oprB mutant grow-
ing slightly better and the gtrS mutant growing slightly worse.
Figure 1. Glucose uptake and utilisation mutants have attenuated growth in minimal medium.  
P. aeruginosa PAO1 glucose uptake operon (A). Location of glucose uptake and utilisation genes in P. aeruginosa 
carbon metabolism pathway, genes selected for deletion underlined (B). Growth of mutant strains Δ oprB, Δ 
gltK, Δ gtrS and Δ glk was assessed by optical density after inoculation of overnight cultures 1:100 in LB (C), M9 
with 50 mM glucose (D), 50 mM fructose (E) or 50 mM succinate (F). Points represent the mean + /− SD of 
n = 3 replicates. * p < 0.01, * * * p < 0.001 between PAO1 and other mutants at different glucose concentrations, 
#p < 0.05, ###p < 0.001 between ΔoprB and ΔgtrS by two way ANOVA with post test.
www.nature.com/scientificreports/
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In previous studies we observed that glucose availability is tightly regulated at epithelial surfaces and that 
increasing the basolateral glucose can increase apical bacterial growth8,9. Using a similar model (Fig. 2A), we 
observed a significantly increased recovery of PAO1 bacteria from the apical surface of airway epithelial mon-
olayers when the basolateral glucose concentration was increased to 50 mM (p < 0.05, Fig. 2B). Growth of the 
mutant strains was significantly impaired when co-cultured with airway epithelial cells. Increasing either basolat-
eral (Fig. 2B) or apical (Fig. 2C) glucose concentration did not increase apical recovery of the mutants. Glucose 
appears to be the only carbon source available at the apical surface because the mutant strains grew to the same 
level as the wild type when grown in the cell culture media used for the studies, without epithelial cells (Fig. 2D). 
Overall, these data demonstrate that deletion of genes involved in glucose uptake and utilisation reduced the 
capacity of P. aeruginosa to grow when glucose is the sole carbon source.
Acute hyperglycaemia increases airway bacterial load in wild type but not in glucose uptake 
and utilisation mutants. To assess the impact of lung glucose on bacterial lung infection, we induced acute 
hyperglycaemia in mice prior to infection by treating with streptozocin (STZ). STZ pre-treatment significantly 
increased blood glucose level concentration (mean STZ 16.3 + /− 1.6 mM, naïve 8.7 + /− 0.5 mM p < 0.001, 
Fig. 3A). Critically, airway glucose level concentration was significantly increased by STZ pre-treatment (mean 
STZ 365.7 + /− 26.3 μ M, naïve 105.7 + /− 10.6 μ M p < 0.001, Fig. 3B). Mice were infected with 106 CFU of log 
phase P. aeruginosa in a 100 μ l volume intranasally (i.n.), pre-treatment with STZ significantly increased the 
amount of recovered bacteria from the airways (measured in bronchoalveolar lavage: BAL) at 24, 48 and 72 hours 
after infection, delaying bacterial clearance (p < 0.01, Fig. 3C). The glucose levels in the blood were consistently 
higher in the STZ treated mice than the naïve mice throughout the experiment. Markers of an inflammatory 
immune response were similar in both groups, independent of hyperglycaemia. Both groups of animals displayed 
an acute, transitory weight loss (Fig. 3D) with cell recruitment to the airways consisting mostly of neutrophils 
(Fig. 3E), the proportion of which declined as the infection was cleared in the naïve group, but more slowly in 
the STZ group, potentially reflecting the delayed bacterial clearance. Infection significantly increased levels of 
Figure 2. Glucose uptake and utilisation mutants have attenuated growth in airway epithelium co-culture 
supplemented with glucose. A549 cells were grown on transwell inserts to form monolayers at air liquid 
interface, transwell resistance measurements were taken to ensure epithelial integrity. The basolateral (B) or 
apical (C) concentration of glucose was altered and 104 CFU bacteria added to the apical side and incubated at 
37%, 5% CO2 for 4 hours. After 4 hours the apical side bacterial numbers were determined by serial dilution. 
Growth of mutant strains Δ oprB, Δ gltK, Δ gtrS and Δ glk was assessed by optical density after inoculation of 
overnight cultures 1:100 in F12 cell culture media (D). Bars represent the mean + /− SD of n = 3 replicates,  
* p < 0.01, * * * p < 0.001 between PAO1 at different glucose concentrations, ###p < 0.001 between wild type 
PAO1 and the mutants at the same glucose concentration by two way ANOVA with post test.
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the pro-inflammatory cytokine IL-6 at 24 hours after infection in the airways (Fig. 3F), which declined as the 
infection was cleared.
We then compared the growth of the glucose mutants with the parental strain PAO1 in STZ treated or control 
naïve mice. This experiment readily showed that there were far more PAO1 bacteria recovered from the airways 
in STZ treated as compared to naive mice (p < 0.05, Fig. 4A). However, STZ induced hyperglycaemia did not 
increase the recovery of the glucose mutants, the fold change between naïve and STZ treated was significantly 
greater for PAO1 infected animals(Fig. 4B). In the naïve (STZ untreated) mice, there was no difference in the bac-
terial load following infection with either the parental PAO1 or the mutant bacteria. The airway glucose was sig-
nificantly greater during GltK infection of STZ treated mice than naïve animals. Beyond the striking differences 
in airway bacterial load in STZ treated animals, there was no difference when using different bacteria in terms of 
the inflammatory responses, with similar neutrophil recruitment (Fig. 4D) and inflammatory cytokine responses 
(Fig. 4E). Overall, these data show that streptozocin-induced hyperglycaemia in mice led to a higher bacterial 
burden on infection which is linked directly with the ability of the bacteria to metabolise glucose.
Figure 3. Acute hyperglycaemia leads to increased bacterial load after wild type PAO1 infection. Mice 
were injected with 2 doses of 10 mg/dose streptozocin intraperitoneally (STZ, closed squares) or untreated 
(open squares). Glucose was measured in blood (A) or BAL (B) prior to infection. Log phase growth PAO1 
was administered intranasally at a concentration of 106 CFU/mouse. Bacterial burden was measured in BAL 
(C). Weight change was measured (D) and percentage airway neutrophils (E) and IL-6 were measured in the 
BAL (F). Points represent individual mice (A–C,E,F) or mean + /− SD of n = 5 animals . Lines represent mean 
values. * p < 0.05, * * p < 0.01, * * * p < 0.001, calculated using multiple t tests with weighted corrections.
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Treatment with metformin significantly reduces airway bacterial load in hyperglycaemic 
mice. Controlling airway glucose may provide a novel approach to control bacterial lung infection in diabe-
tes. To test this we used the anti-diabetic drug metformin. After induction of hyperglycaemia using streptozo-
cin, mice were treated with metformin prior to infection. Streptozocin treatment significantly increased blood 
(Fig. 5A) and airway (Fig. 5B) glucose prior to infection. Metformin treatment did not change blood glucose 
levels but reduced BAL glucose levels to the same as naïve animals. Strikingly, pre-treatment with metformin led 
to a significant reduction in the airway bacterial load (Fig. 5C, p < 0.05). There was no significant difference in the 
number of neutrophils (Fig. 5D) or IL-6 (Fig. 5E) regardless of treatment regime.
Discussion
In this study we demonstrated a clinical association between high blood glucose and respiratory tract bacterial 
colonisation. We also show that hyperglycaemia induced increases in airway surface liquid glucose concentra-
tion were associated with increased airway bacterial load, using P. aeruginosa with targeted gene deletions in the 
glucose metabolism pathway. The use of the P. aeruginosa mutants is key and instrumental to point out the direct 
relationship between bacterial load and the ability to use glucose or not. The genes we chose to delete are involved 
in various stages of the uptake and metabolism of glucose, which ensures specificity and avoids pleotropic effects. 
The in vitro growth of these mutants was shown to be identical to the parental strain in LB or minimal medium 
supplemented with fructose, whereas growth was drastically affected when glucose was the only carbon source. 
Interestingly, the gtrS mutant was further attenuated in either succinate or glucose supplemented media, which 
may reflect the gtrS protein’s role as a regulator. The recovered CFU of the PAO1Δ oprB strain was higher than 
PAO1 in succinate supplemented minimal media, which may be caused by the relaxation of catabolite repression 
in the mutant strain20. The genes deleted in this study were highly targeted as compared to previous studies which 
used edd gene mutants of P. aeruginosa6, which are affected in the metabolism of several different carbon sources, 
not only glucose21 and were unable to grow in either control or hyperglycaemic animals.
Using in vitro airway epithelia-bacteria co-cultures, we observed a significant reduction in the growth of all 
glucose mutants. Compared to the parental strain, bacterial recovery after infection with the mutants was lower 
even when glucose was increased. There was no difference in bacterial growth observed in the F12 media alone, 
which in addition to glucose contains pyruvate and amino acids. Taken together, this suggests that the main 
utilisable carbon source for P. aeruginosa at the airway epithelial surface in the co-culture system in vitro is glu-
cose. However, in normal mouse lungs the glucose mutants were not attenuated compared to the parental strain, 
which suggests that unlike the in vitro system, there are other carbon sources available in the lungs. Interestingly 
airway glucose remained significantly higher 24 hours after infection in STZ treated Δ gltK infected animals 
than naïve animals infected with the same bacteria, possibly reflecting the role of GltK as glucose uptake pore. 
Understanding what other carbon sources are available to bacteria in the lungs may open up alternative interven-
tion strategies.
Controlling airway glucose concentration is one example of a number of non-immune mechanisms that have 
evolved to prevent bacterial infection. Glucose is not the only nutrient that is restricted in the airways, levels of amino 
acids and other carbon sources are also limited22. Interactions and competition between microbes for this limited 
resource can lead to altered virulence of the bacteria23. Glucose is also important in host immune function and bacterial 
Figure 4. Hyperglycaemia increases acute bacterial load in mice infected with WT but not knockout 
strains. Mice were injected with 2 doses of 10 mg/dose Streptozocin (STZ) intraperitoneally, and mice were 
infected intranasally with 106 CFU/mouse of either WT PAO1 or mutant strains and sacrificed after 24 hours. 
BAL CFU (A), fold change in BAL CFU between STZ and control animals (B), BAL neutrophilia (C) and IL-6 
(D) were assessed at 24 hours after infection. Points represent individual mice, lines represent mean values, 
bars represent mean + /− SEM of n = 5 animals. * p < 0.05, calculated using multiple t tests with weighted 
corrections.
www.nature.com/scientificreports/
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Figure 5. Metformin reduces airway bacterial load after wild type PAO1 infection in hyperglycaemic 
mice. Mice were injected with 2 doses of 10 mg/dose Streptozocin (STZ) intraperitoneally. On d-2, d-1 and 
d0 of infection, one group of mice received a 200 μ l dose of 4 mg/ml i.p. metformin (MF). Blood glucose was 
measured before and after drug treatment (A). BAL glucose was measured after drug treatment (B). Mice 
were infected intranasally with 106 CFU/mouse of WT PAO1 and sacrificed after 24 hours. BAL CFU (C), 
neutrophilia (D) and IL-6 (E) were assessed at 24 hours after infection. Points represent individual mice. Lines 
represent mean values. * p < 0.05, calculated using multiple t tests with weighted corrections.
www.nature.com/scientificreports/
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exposure bacteria can increase cellular glucose uptake9, the competition between host cells and bacteria for airway 
nutrients is of interest and needs further research, especially the effect of metformin on the host immune cells. In addi-
tion to directly affecting bacterial growth and survival, airway surface liquid chemistry has an effect on the secretion 
and action of antimicrobial molecules. Airway surface pH has been demonstrated to be critical for the function of 
antimicrobial activity in the lungs24. Glucose can inhibit the secretion of anti-microbial peptides in the airways induced 
by bitter taste receptors25 and glucose inhibits the function of surfactant protein D26.
There were a number of experimental limitations that need to be considered. One of the limitations of the 
study is that we were not able to separate the effect of elevated glucose on the host response from the effect 
of elevated glucose on the bacteria. It has previously been asserted that increased bacterial infection in diabe-
tes is driven by underlying immunodeficiencies27 and it is likely that elevated glucose levels alters the immune 
response. Whilst we only performed a limited analysis of the immune response, we saw no differences in the 
immune parameters measured, airway neutrophilia and IL-6, between the hyperglycaemic and control animals. 
But we did, however, observe an association between elevated airway glucose and bacterial load, which was only 
seen in glucose metabolism competent bacteria. A second limitation is that streptozocin induced hyperglycaemia 
in mice is not the same as diabetes in patients: however, similar increases in bacterial loads have been observed 
in two other models of hyperglycaemia, leptin (ob/ob)6 and leptin receptor (db/db)8 deficient mice. Finally, the 
mutants we generated were only specific for glucose and therefore, it may be that other carbon sources are ele-
vated in the airways in hyperglycaemia enabling bacterial growth, which is of interest and would need to be tested 
in other studies. Even taking these limitations into account we still believe that our work strongly supports the 
hypothesis that elevated airway glucose drives increased bacterial growth.
The manipulation of airway surface liquid chemistry may offer alternative avenues to control lung bacterial 
infection than conventional antibiotics, which are becoming less effective for many of the main causes of bacte-
rial respiratory infection. Treatment with metformin reduced airway glucose levels in hyperglycaemic animals 
and significantly reduced bacterial load in the airways. We have recently observed a similar effect after S. aureus 
infection in obese mice treated with metformin8, demonstrating the breadth of this approach as it can reduce 
bacterial load after infection with either gram positive or negative bacteria. Metformin usage is safe in patients 
with COPD28 and an ongoing clinical trial is exploring whether metformin can reduce COPD exacerbations 
(NCT01247870). These approaches have the advantage of targeting host mechanisms, which may be harder for 
the pathogen to escape. These new findings thus indicate that hyperglycaemia has the potential to drive respira-
tory infection in the absence of other hallmarks of diabetic disease with implications for human health. Our work 
thus opens up novel strategic targets for the control of bacterial lung infection in the most at risk patients.
Methods
Critical Care admissions database. An established anonymised research database was interrogated to 
elicit demographic information, blood glucose levels (highest recorded on day of critical care admission) and 
culture positive microbiology results during the first 7 days of the critical care admission. All admissions to two 
central London teaching hospital critical care units (belonging to a hospital network with overarching governance 
structures, policies and who share a centralised laboratory which observes national standard operating proce-
dures) were included for the fiscal year 2013–2014 (in the UK fiscal years run April to March). Where multiple 
isolates were grown, only the first was selected. Extraction, pseudoanonymisation, and analysis of the clinical 
epidemiological data in this study was conducted after review by, and with the approval of, the Imperial College 
London Joint Research Compliance Office (ref. 13 HH0747).
Gene deletion. The laboratory strain PAO129 was used throughout this study. Deletion of glucose uptake 
and utilisation genes (oprB, gltK, gtrS and glk) in the PAO1 background was generated as previously described19. 
Briefly, PCR amplification of DNA flanking the gene of interest was used to generate a mutator fragment which 
was then cloned into the suicide vector PKNG101 carrying the gene conferring SmR and the sucrose selection 
gene sacB. Through a series of recombination events the gene of interest is deleted and the insert removed upon 
selection on sucrose-containing plates. Successful gene deletion was confirmed by PCR.
Bacterial growth characterisation. Bacteria were plated out on Lysogeny Broth (LB) agar (Sigma) to 
single colonies prior to overnight growth in 5 ml liquid LB. 1:100 dilution of overnight culture was inoculated into 
5 ml LB and growth assessed by optical density (OD600). Bacterial growth was assessed in LB and M9 minimal 
salts media supplemented with 50 mM succinate or glucose where indicated.
Polarised airway epithelia-bacteria co-cultures. A549 cells were cultured and grown in F-12 media 
supplemented with fetal calf serum and L-glutamine on transwell inserts. Prior to infection, transwell resistance 
(RT) measurements were taken to ensure epithelial integrity using an Ohmmeter (Millicell ERS-2 Ohmmeter) 
and rejected if < 100Ω. P. aeruginosa was prepared by inoculating fresh LB with overnight culture and grown 
to a log phase OD600 of 0.4 log phase (approximately 107 CFU/ml determined by confirmed by plating out serial 
dilutions). Cultures were diluted to 105 CFU/ml in PBS and 100 μ l applied to the apical side. Co-cultures were 
incubated at 37 °C, 5% CO2 for 4 hours. After 4 hours the epithelial cells and bacteria were homogenised and seri-
ally diluted to determine CFUs from the apical side.
In vivo models. 6–8 week old female C57BL/6 mice were obtained from Harlan UK Ltd (Logosenn, Truro, 
UK) and kept in specific-pathogen-free conditions in accordance with the United Kingdom’s Home Office guide-
lines and approved by the Animal Welfare and Ethical Review Board (AWERB) at Imperial College London. 
Mice were infected with 106 CFU of log phase P. aeruginosa in a 100 μ l volume intranasally (i.n.). Where per-
formed, hyperglycaemia was induced using the drug streptozocin (STZ) which was administered by intraperi-
toneal (i.p.) injection at a concentration of 10 mg/mouse in 0.5 ml on day − 14 and day − 7 prior to infection. 
www.nature.com/scientificreports/
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Glucose was monitored by taking blood from the tails of mice and using a OneTouch UltraEasy blood glucose 
monitor and OneTouch UltraEasy Test Strips (LifeScan, UK) and urine glucose was monitored using Diastix 
reagent sticks (Bayer Diagnostic Fisher). BAL glucose was measured post infection by High Performance Liquid 
Chromatography (HPLC) as previously described30 , or amplex red glucose/glucose oxidase assay kit (Invitrogen). 
When used, mice were pre-treated with 200 μ l 4 mg/ml of metformin (Sigma) i.p. on days − 2, − 1 and 0 prior to 
infection.
Tissue and cell recovery and isolation. Mice were culled using i.p. pentobarbitone. Bronchoalveolar 
lavage (BAL) was obtained by inflating the lungs via an intratracheal cannula with PBS. Lungs were removed 
and homogenised by passage through 100 μ m cell strainers. Bacterial loads were determined in untreated BAL 
and lung homogenate by serial dilution as described31 on Pseudomonas isolation agar (Sigma, UK) using a mul-
tichannel pipette. After plating for bacterial load, lung samples and BAL were treated with red blood cell lysis 
buffer before centrifugation at 200 × g for 5 minutes. Cells were resuspended in RPMI medium with 10% fetal 
calf serum and viable cell numbers determined by trypan blue exclusion. For differential cell counts, 100 μ l of 
cells from BAL and the lung homogenate were centrifuged onto glass slides. Samples were air dried, and fixed 
in methanol, before staining of with haematoxylin and eosin. Cytokines were assessed by ELISA (R&D systems) 
following manufacturer’s instructions.
Statistical analysis. Clinical data were statistically analysed using Chi squared or Fisher’s exact test as 
appropriate in STATA® IC 13 (TX). For the in vitro and in vivo models comparisons of two groups were per-
formed using Student’s t tests. Comparisons of multiple groups were performed using one- or two-way ANOVA 
with appropriate post-tests. All statistical tests were performed using GraphPad Prism version 6.01 for Windows 
(GraphPad Software, San Diego California USA).
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